2pm GMT | 3pm CET | 9am CDT | 10am EDT
Join experts David Ponting (Principal Scientist, Lhasa Limited) and Natan Segretti (CSO, Consult Lhasa) for an explorative webinar on the recently updated EMA guidelines for nitrosoureas risk assessment.
Natan will provide a comprehensive overview of this critical regulatory update, explaining why nitrosoureas are classified within the cohort of concern and the reasoning behind these new regulatory changes.
Following this, David will deliver a practical demonstration of our in silico read-across tool, Acrostic. Through a detailed nitrosourea case study, attendees will witness first hand how the software can be effectively utilised to determine acceptable intake limits for nitrosoureas in accordance with the latest EMA requirements.
What you’ll learn:
- A comprehensive understanding of the updated EMA guidelines on nitrosoureas and why these compounds require regulatory attention.
- Practical insights into applying in silico read-across methodology for nitrosoureas evaluation using Acrostic.
- Effective strategies for establishing evidence-based acceptable intake limits that align with regulatory expectations while supporting your scientific goal.
There will also be an opportunity to take part in a live Q&A. Register to secure your place.